InDevR Launches 5’CapQ for Rapid Quality Testing of mRNA-Based Vaccines

BOULDER, CO / ACCESSWIRE / June 25, 2024 - InDevR Inc., a pioneer in analytical solutions for vaccine testing, has introduced 5'Cap Q to swiftly determine the 5' capping efficiency of mRNA. The kit, now available for the VaxArray Platform, allows vaccine manufacturers to get results within two hours, eliminating the need for central lab waiting times.

The 5' cap structure is essential for mRNA protection and efficient translation. Accurate measurement of the 5' cap and capping efficiency is crucial for the effectiveness of mRNA vaccines. Traditionally, this analysis involves sending samples to a central lab, a process that can take days. With 5'Cap Q, scientists can now perform these tests on-site, reducing turnaround time significantly.

InDevR collaborates with biopharmaceutical groups to create customized testing solutions for critical quality attributes (CQA). According to CEO Kathy Rowen, PhD, 5'Cap Q enables scientists to obtain essential CQA insights quickly, potentially extending its utility beyond mRNA vaccines to other therapeutic applications.

5'Cap Q is among many innovative kits designed for the VaxArray Platform. This benchtop instrument, along with its ready-to-use kits, streamlines vaccine development processes, from early stages to clinical evaluation and potency testing.

For more details about 5'Cap Q and its impact on vaccine production, visit indevr.com/5CapQ.